<DOC>
	<DOCNO>NCT00490451</DOCNO>
	<brief_summary>The primary purpose study estimate time first dose LY573636 date physician determine disease progress worsen .</brief_summary>
	<brief_title>A Study LY573636-Sodium Treatment Patients With Metastatic Soft Tissue Sarcoma</brief_title>
	<detailed_description>Patients receive 2-hour intravenous infusion study drug ( LY573636 ) every 21 day 28 day depend target dose . Radiological imaging scan perform first dose study drug every treatment . Patients assess clinical progression every visit response approximately every 42 day 56 day ( every cycle ) .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<criteria>Diagnosis soft tissue sarcoma unresectable metastatic Have receive one two ( two ) prior treatment regimens metastatic soft tissue sarcoma , one must include doxorubicin ( adriamycin ) . Must stop previous treatment cancer , include chemotherapy , radiation therapy investigational treatment cancer least 30 day Patients primary bone sarcoma ( e.g . osteosarcoma , Ewing 's sarcoma , chondrosarcoma ) , gastrointestinal stromal tumor ( GIST ) Kaposi 's sarcoma Serious preexist medical problem ( determine doctor ) Have receive two previous systemic treatment regimen unresectable metastatic soft tissue sarcoma Have second primary cancer ( unless cancerfree 2 year ) Active treatment Warfarin ( Coumadin )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>